Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
Follow-Up Questions
Vicapsys Life Sciences Inc의 CEO는 누구입니까?
Mr. Federico Pier은 2019부터 회사에 합류한 Vicapsys Life Sciences Inc의 Chief Executive Officer입니다.
VICP 주식의 가격 성능은 어떻습니까?
VICP의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Vicapsys Life Sciences Inc의 주요 사업 주제나 업종은 무엇입니까?
Vicapsys Life Sciences Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
